Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
US6399826B1 · kind B1 · utility
0Cited by
37References
5Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 11, 2000 |
| Grant date | Jun 4, 2002 |
| Priority date | — |
| Expiry date | Jan 11, 2020 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07C2601/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods of making and using racemic and optically pure metabolites of sibutramine, and pharmaceutically acceptable salts, solvates, and clathrates thereof, are disclosed. Pharmaceutical compositions and dosage forms are also disclosed which comprise a dopamine reuptake inhibitor, such as a racemic or optically pure sibutramine metabolite, and optionally an additional pharmacologically active compound.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.